John Hrom

Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification

Brendan Bulik‐Sullivan, Jennifer Busby, Christine D. Palmer et al. · Nature Biotechnology · 2018 · 310 citations

Medicine, Molecular Biology, Oncology +17

Tissue microarray constructs to predict a response to chemoradiation in rectal cancer

Sergio Huerta, John Hrom, Xiaohuan Gao et al. · Digestive and Liver Disease · 2010 · 36 citations

Medicine, Bioinformatics, Oncology +14

Replacement of ixazomib for relapsed/refractory multiple myeloma patients refractory to a bortezomib or carfilzomib-containing combination therapy.

James R. Berenson, Alexa Cohen, Tanya M. Spektor et al. · Journal of Clinical Oncology · 2017 · 11 citations

Medicine, Pharmacology, Pharmacotherapy +15

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-203)

Ryan C. Lynch, Abraham Avigdor, Matthew McKinney et al. · Blood · 2021 · 11 citations

Medicine, Oncology, Pharmacotherapy +7

Phase 2 Study of Carfilzomib (CFZ) with or without Filanesib (FIL) in Patients with Advanced Multiple Myeloma (MM)

Jeffrey A. Zonder, Saad Z. Usmani, Emma C. Scott et al. · Blood · 2015 · 10 citations

Medicine, Hematology, Pharmacology +14